212 results on '"Shao, Yu-Yun"'
Search Results
2. Changes in Posttreatment Spleen Volume Associated with Immunotherapy Outcomes for Advanced Hepatocellular Carcinoma
3. Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma
4. Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
5. Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma
6. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
7. Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study.
8. The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
9. Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
10. Potential of Circulating Immune Cells as Biomarkers of Nivolumab Treatment Efficacy for Advanced Hepatocellular Carcinoma
11. Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study
12. Abstract 5985: Cyclin dependent kinase 9 (CDK9) inhibition increased efficacy of programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma (HCC) through decreasing programmed death-ligand 1 (PD-L1) expression
13. Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan
14. Key opioid prescription concerns in cancer patients: A nationwide study
15. Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants
16. Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer.
17. Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma
18. High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma
19. Additional file 1 of Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
20. Immune-related neuromuscular junction disorder after immune checkpoint inhibitor treatment
21. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
22. Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
23. Impact of expanded strong opioid availability on opioid prescription patterns in patients with cancer: A population-wide cohort study in Taiwan
24. Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy
25. Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials
26. Young patients with colorectal cancer have increased risk of second primary cancers
27. Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma
28. Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma
29. An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma
30. An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma
31. It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade
32. Reply to letter to the editor: Low skeletal muscle mass are predictive factors of survival for advanced hepatocellular carcinoma
33. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma
34. Abstract 1590: High ICOS/FOXP3 Tregs content in the tumor microenvironment is associated with poorer survival in patients with hepatocellular carcinoma
35. A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
36. Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin
37. Neutrophil–to–lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
38. Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma
39. Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
40. A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma
41. Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
42. Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure
43. Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells
44. Right or left? Side selection for a totally implantable vascular access device: a randomised observational study
45. Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study
46. National Policies Fostering Hospice Care Increased Hospice Utilization and Reduced the Invasiveness of End-of-Life Care for Cancer Patients
47. P3.07-009 Use of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: The Real-World Clinical Practice in Taiwan
48. Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
49. Abstract 2831: Composite cyclin dependent kinase inhibition shows potent activity against hepatocellular carcinoma
50. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.